Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gonadorelin Acetate

FDA-approved product (injectable, injection), marketed as Lutrepulse Kit, Factrel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gonadorelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Gonadorelin Acetate. Its therapeutic class is shown instead.

WHO therapeutic group
Gonadotropin-releasing hormones; Tests for fertility disturbances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gonadorelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gonadorelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

    NCT03931915 · start 2019-05-08

    Registered record
    Registry ID
    NCT03931915
    Conditions
    Endometriosis
    Interventions
    TAK-385; Leuprorelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-05-08
    Completion
    2020-09-28
    Enrolment
    335

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionTAK-385; Leuprorelin acetate
    PhasePhase 3
    Registry statusCompleted

  • A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

    NCT03809000 · start 2019-04-15

    Registered record
    Registry ID
    NCT03809000
    Conditions
    Prostate Cancer
    Interventions
    Radiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-04-15
    Completion
    2029-09-15
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionRadiation Therapy; Enzalutamide; Bicalutamide; GnRH analog
    PhasePhase 2
    Registry statusActive not recruiting

  • Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

    NCT03839823 · start 2019-02-25

    Registered record
    Registry ID
    NCT03839823
    Conditions
    Breast Cancer
    Interventions
    Docetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib; Letrozole OR Anastrozole; Goserelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-02-25
    Completion
    2023-05-10
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionDocetaxel / Capecitabine; Capecitabine / Vinorelbine; Paclitaxel / Gemcitabine; Ribociclib +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

    NCT03695237 · start 2018-10-24

    Registered record
    Registry ID
    NCT03695237
    Conditions
    Central Precocious Puberty (CPP)
    Interventions
    Leuprolide Acetate (LA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-24
    Completion
    2023-11-29
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty (CPP)
    InterventionLeuprolide Acetate (LA)
    PhasePhase 3
    Registry statusCompleted

  • Comparison of a Novel Leuprolide With Market Leuprolide

    NCT03662958 · start 2018-08-01

    Registered record
    Registry ID
    NCT03662958
    Conditions
    Prostate Cancer
    Interventions
    Lutrate; Enantone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-08-01
    Completion
    2018-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLutrate; Enantone
    PhaseNot applicable
    Registry statusUnknown

  • Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET

    NCT04268927 · start 2018-04-01

    Registered record
    Registry ID
    NCT04268927
    Conditions
    Infertility
    Interventions
    GnRH ant/letrozole; GnRH ant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-04-01
    Completion
    2020-04-20
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionGnRH ant/letrozole; GnRH ant
    PhasePhase 2
    Registry statusUnknown

  • Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual.

    NCT05304169 · start 2017-11-14

    Registered record
    Registry ID
    NCT05304169
    Conditions
    Prostate Cancer
    Interventions
    Leuprorelin Acetate (Eligard® 45 mg).
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-14
    Completion
    2020-06-15
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprorelin Acetate (Eligard® 45 mg).
    PhasePhase 4
    Registry statusCompleted

  • Hormonal Mechanisms of Sleep Restriction - Axis Study

    NCT03142893 · start 2017-05-08

    Registered record
    Registry ID
    NCT03142893
    Conditions
    Sleep Restriction
    Interventions
    Ketoconazole Pill; Ganirelix; Dexamethasone; Dexamethasone Injection; Cosyntropin Injectable Product; Recombinant Human Luteinizing Hormone; Hydrocortisone Injection; Gonadorelin; Corticorelin; Placebo oral capsule; Saline Solution; Saline Solution for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2017-05-08
    Completion
    2026-06-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Restriction
    InterventionKetoconazole Pill; Ganirelix; Dexamethasone; Dexamethasone Injection +8 more
    PhasePhase 1
    Registry statusActive not recruiting

  • Menopause Effects on Vascular Function

    NCT03236545 · start 2016-07-01

    Registered record
    Registry ID
    NCT03236545
    Conditions
    Cardiovascular Risk Factor
    Interventions
    No to Low Endogenous Estrogen; Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07-01
    Completion
    2022-11-01
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Risk Factor
    InterventionNo to Low Endogenous Estrogen; Estradiol
    PhaseNot applicable
    Registry statusCompleted

  • A Study of Definitive Therapy to Treat Prostate Cancer

    NCT02716974 · start 2016-06

    Registered record
    Registry ID
    NCT02716974
    Conditions
    Prostate Cancer
    Interventions
    Leuprolide Acetate; Bicalutamide; Docetaxel; Prostatectomy; Radiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06
    Completion
    2022-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprolide Acetate; Bicalutamide; Docetaxel; Prostatectomy +1 more
    PhasePhase 2
    Registry statusCompleted

  • Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate

    NCT02974270 · start 2016-06

    Registered record
    Registry ID
    NCT02974270
    Conditions
    Precocious Puberty, Central
    Interventions
    Leuprolide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-06
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrecocious Puberty, Central
    InterventionLeuprolide
    PhasePhase 4
    Registry statusUnknown

  • Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

    NCT03209492 · start 2016-04-01

    Registered record
    Registry ID
    NCT03209492
    Conditions
    Prostate Cancer
    Interventions
    Leuprorelin acetate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-04-01
    Completion
    2017-12-01
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprorelin acetate
    PhaseNot recorded
    Registry statusCompleted

  • A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

    NCT02655237 · start 2016-03-05

    Registered record
    Registry ID
    NCT02655237
    Conditions
    Uterine Fibroids
    Interventions
    Relugolix; Relugolix Placebo; Leuprorelin; Leuprorelin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03-05
    Completion
    2017-09-25
    Enrolment
    281

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Fibroids
    InterventionRelugolix; Relugolix Placebo; Leuprorelin; Leuprorelin Placebo
    PhasePhase 3
    Registry statusCompleted

  • Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

    NCT02168062 · start 2014-06-16

    Registered record
    Registry ID
    NCT02168062
    Conditions
    Prostate Adenocarcinoma
    Interventions
    Behavioral Dietary Intervention; Counseling; Educational Intervention; Exercise Intervention; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate; Quality-of-Life Assessment; Triptorelin Pamoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-06-16
    Completion
    2018-05-22
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma
    InterventionBehavioral Dietary Intervention; Counseling; Educational Intervention; Exercise Intervention +5 more
    PhasePhase 2
    Registry statusTerminated

  • A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone

    NCT03211052 · start 2013-02-18

    Registered record
    Registry ID
    NCT03211052
    Conditions
    Prostate Cancer
    Interventions
    TAK-700 and LHRH agonist; prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-02-18
    Completion
    2015-06-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTAK-700 and LHRH agonist; prostatectomy
    PhasePhase 2
    Registry statusTerminated